Clinical trial
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant…
NCT00345540 · Cellectar Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00345540 |
|---|---|
| Title | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer |
| Official title | Phase 2 Trial of NOV-002 With Carboplatin in Women With Recurrent and Platinum Resistant Tumors of Mullerian Origin |
| Lead sponsor | Cellectar Biosciences, Inc., Industry |
| Collaborators | Massachusetts General Hospital Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | NOV-002, Carboplatin |
| Enrollment | 15 |
| Start date | Jul 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jun 28, 2006 |
| Last update posted | Mar 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: